The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-04), PureTech Health's 9-Day RSI is 29.95.
The industry rank for PureTech Health's 9-Day RSI or its related term are showing as below:
LSE:PRTC's 9-Day RSI is ranked better than 86.85% of 1422
companies
in the Biotechnology industry
Industry Median: 51.47
vs LSE:PRTC: 29.95
PureTech Health (LSE:PRTC) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
PureTech Health 9-Day RSI Related Terms
LSE:PRTC vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, PureTech Health's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where PureTech Health's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health (LSE:PRTC) has a 9-Day RSI of 29.95 as of Jul. 04, 2026. According to the industry distribution chart, PureTech Health ranks #187 out of 1422 companies in the Biotechnology industry, placing it in the top 13.2%.
Is PureTech Health's 9-Day RSI too high?
PureTech Health's current 9-Day RSI is 29.95. The Biotechnology industry median 9-Day RSI is 51.47. PureTech Health's value of 29.95 is 41.8% below this industry median. Based on the distribution chart, PureTech Health ranks #187 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PureTech Health has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #187 out of 1422 companies for 9-Day RSI. This places PureTech Health in the top 13% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 51.47. PureTech Health's value of 29.95 is 41.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 51.47, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PureTech Health's current 9-Day RSI of 29.95 is 41.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 51.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PureTech Health's current 9-Day RSI is 29.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (LSE:PRTC) is currently considered Possible Value Trap. The stock's GF Value™ is £5.29, compared to a current price of £1.20 — trading 77.3% below its estimated fair value. The current 9-Day RSI is 29.95 and 41.8% below the Biotechnology industry median of 51.47. PureTech Health's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For PureTech Health (LSE:PRTC), the current 9-Day RSI is 29.95 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (LSE:PRTC) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of £1.20 is trading 77.3% below its estimated GF Value™ of £5.29.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for LSE:PRTC:
9-Day RSI: 29.95
GF Value™: £5.29 vs. price of £1.20 (77.3% below fair value)
Industry Position: 41.8% below the Biotechnology median (#187 of 1422)
No single metric tells the full story. See the LSE:PRTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
64GF Score
Get the complete analysis for LSE:PRTC
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:PRTC has been successfully added to your 